Close
CDMO Safety Testing 2026
Novotech

Global market will reach $26 billion by 2020, says GBI Research

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Bioprocess Analytics Improving Biologics Manufacturing

The immense complexity of modern biopharmaceutical production is being navigated through the strategic and systematic application of bioprocess analytics improving biologics manufacturing. By leveraging real-time data streams and advanced monitoring tools, manufacturers can gain a granular, molecular-level understanding of cellular behavior and the surrounding environmental conditions within the bioreactor. This proactive, data-driven approach allows for immediate, automated adjustments that optimize therapeutic yield, ensure absolute product consistency, and significantly streamline the arduous path toward commercial-scale production in a highly regulated global environment.

Cell Therapy Quality Control Improving Clinical Outcomes

The long-term success of advanced medicinal products is fundamentally dependent on a rigorous and comprehensive approach to cell therapy quality control improving clinical outcomes. By implementing stringent, multi-stage testing for identity, purity, potency, and safety, manufacturers can guarantee that every individual dose delivered to a patient meets the highest possible standards of GMP compliance. This systematic and data-driven oversight minimizes clinical risks and enhances the reproducibility of complex treatments, ultimately leading to more predictable and successful therapeutic results in the rapidly evolving field of regenerative medicine.

GMP Cytokines Advancing Cell Therapy Manufacturing

The rapid transition of cell-based treatments from the experimental laboratory stage to the standard of clinical care is being enabled by the availability of GMP cytokines advancing cell therapy manufacturing. These vital signaling molecules are absolutely essential for the successful expansion, specific differentiation, and functional activation of therapeutic cell populations, such as CAR T cells used in oncology. By strictly adhering to Good Manufacturing Practice standards, suppliers ensure that these critical raw materials possess the high purity, consistent potency, and clinical safety required for human applications, thereby reducing product variability and significantly enhancing the success rate of regenerative medicine.
- Advertisement -

The global market for drug delivery technologies will rise from $20 billion in 2015 to around $26 billion by 2020, according to business intelligence firm GBI Research.

The company’s latest report states that the emergence of new business models, emphasis on improving drug delivery, growing incidence of chronic diseases, increasing usage of complex medicines and significant technological advancements will continue to drive growth in the drug delivery technologies market to 2020.

North America remains the largest regional market for drug delivery technologies, with the US accounting for the largest market in terms of value and volume.

Deekshita Allavarapu, Analyst for GBI Research, states: “The size of the US market was estimated to be $6.2 billion in 2015 and is projected to grow at a compound annual growth rate (CAGR) of 4.3% from 2010 to reach $7.7 billion in 2020.

“The US drug delivery technologies market will continue to maintain its leading position in the global market during the forecast period due to a rapidly growing aging population, rising prevalence of chronic diseases and new product launches.”

GBI Research also states that Asia-Pacific (APAC) is expected to be the fastest-growing region over the forecast period, with the Indian market expanding at a CAGR of 7.3% from 2010 to 2020 and the Chinese market rising at a CAGR of 5.2% over the same period.

“The fast growth in APAC markets is attributed to the growing population, the rising prevalence of chronic diseases in the region and the need to address a wide range of unmet medical needs.”

– Comments provided by Deekshita Allavarapu, Analyst for GBI Research.
– Information based on GBI’s report: Global Drug Delivery Technologies.
– This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

About GBI Research
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets. GBI Research is a trading name of GlobalData plc.

For more information,
please contact our Press Office on 
+44 (0)161 359 5822 
pr@gbiresearch.com

 

World Pharma Today brings together the global pharmaceutical industry — from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

Bioprocess Analytics Improving Biologics Manufacturing

The immense complexity of modern biopharmaceutical production is being navigated through the strategic and systematic application of bioprocess analytics improving biologics manufacturing. By leveraging real-time data streams and advanced monitoring tools, manufacturers can gain a granular, molecular-level understanding of cellular behavior and the surrounding environmental conditions within the bioreactor. This proactive, data-driven approach allows for immediate, automated adjustments that optimize therapeutic yield, ensure absolute product consistency, and significantly streamline the arduous path toward commercial-scale production in a highly regulated global environment.

Cell Therapy Quality Control Improving Clinical Outcomes

The long-term success of advanced medicinal products is fundamentally dependent on a rigorous and comprehensive approach to cell therapy quality control improving clinical outcomes. By implementing stringent, multi-stage testing for identity, purity, potency, and safety, manufacturers can guarantee that every individual dose delivered to a patient meets the highest possible standards of GMP compliance. This systematic and data-driven oversight minimizes clinical risks and enhances the reproducibility of complex treatments, ultimately leading to more predictable and successful therapeutic results in the rapidly evolving field of regenerative medicine.

GMP Cytokines Advancing Cell Therapy Manufacturing

The rapid transition of cell-based treatments from the experimental laboratory stage to the standard of clinical care is being enabled by the availability of GMP cytokines advancing cell therapy manufacturing. These vital signaling molecules are absolutely essential for the successful expansion, specific differentiation, and functional activation of therapeutic cell populations, such as CAR T cells used in oncology. By strictly adhering to Good Manufacturing Practice standards, suppliers ensure that these critical raw materials possess the high purity, consistent potency, and clinical safety required for human applications, thereby reducing product variability and significantly enhancing the success rate of regenerative medicine.

Recombinant Proteins Driving Biologics Innovation

The landscape of modern therapeutic development is being fundamentally reshaped by the precision of recombinant proteins driving biologics innovation. These highly engineered molecules serve as the foundational architecture for initial drug discovery, the creation of sophisticated high-throughput assay development, and the eventual transition into large-scale biologics manufacturing. By utilizing advanced protein expression platforms, the pharmaceutical industry can now produce specific, high-purity proteins that effectively mimic complex natural biological functions with extraordinary accuracy, ensuring that new treatments are both safe and potent for global distribution.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »